

**Luke John Halbur, M.D.**

**Ironwood Cancer and Research Centers**

**Division of Oncology and Hematology**

Genitourinary and Gastrointestinal Malignancies

**Education:**

1999-2002 **Fellowship Hematology & Oncology, University of California at Irvine**

2002-2005 **Residency Internal Medicine, University of California at Irvine**  
**Loyola University Stritch School of Medicine**  
Medical Doctorate

1991-1995 **University of California at Irvine**  
Bachelor of Science in Biological Sciences

**Professional Experience:**

2005 – Present Physician, Ironwood Cancer & Research Centers, Mesa, AZ

**Activities and Honors:**

*Certifications:*

American Board of Internal Medicine – 2002

American Board of Internal Medicine – Hematology and Medical Oncology - 2006

*Awards, Honors and Committees:*

Phoenix Magazine Top Doc Award

American Society of Hematology Travel Award – December 2003

Internal Medicine Resident of the Year – 2002

Acceptance and scholarship to AARC/ASCO Clinical Trials Workshop 2004

Member of Medical Executive Committee, 2007- present

**Professional Memberships:**

American Society of Clinical Oncology (ASCO)

American Society of Hematology (ASH)

American Association of Cancer Research (AACR)

American Medical Association

**Publications:**

**Halbur L.,** Ly C, Ong T.: *Inhibition of mTOR by Rapamycin Enhances Killing of CML Cells by Imatinib Mesylate and Overcomes Certain Forms of Imatinib Resistance.* Blood 2003; 102: Abstract 242

Contributing Editor

Internal Medicine P.R.E.P.P. Board Review Book

2001 Edition

Prechel MM, **Halbur L.,** Devata S, Vaida AM, Young MR.: *Increased Interlukin-6 Production by Cerebral Tissue of Adult Versus Young Mice.* Mechanisms of Aging and Development 1996; 92: 185-94

Lifrak ET, Erickson RA, **Halbur L.,** Quimbo E.: *Role of Tumor Necrosis Factor-Alpha in NSAID-Induced Intestinal Ulceration.* Gastroenterology 1995; 108: A149

Lifrak ET, Erickson RA, **Halbur L.,** Macias G and Rivera N.: *Mechanism of Synergism of Nitric Oxide (NO) Inhibition Injury by Nabumetone and Indomethacine.* Gastroenterology 1994; 106: A125

Platform presentation of ASH abstract 242. CML Oral session

45<sup>th</sup> ASH Annual Meeting, December 2003

San Diego, CA

**Research Trials:**

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.

**Other Activities:**

Mountain biking, hiking and cheering on the Suns or Cardinals.